Ciprofibrate

• UNSPSC Description:

  Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha[1]. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias[2].

• Target Antigen:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Ciprofibrate.html

• Purity:

  99.93

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC(C)(OC1=CC=C(C2C(Cl)(Cl)C2)C=C1)C(O)=O

• Molecular Weight:

  289.15

• References & Citations:

  [1]Passilly, P., et al., Phosphorylation of peroxisome proliferator-activated receptor alpha in rat Fao cells and stimulation by ciprofibrate. Biochem Pharmacol, 1999. 58(6): p. 1001-8.|[2]Agnes M Rimando, et al. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem. 2005 May 4;53(9):3403-7.|[3]Thing-Fong Tzeng, et al. 6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism. Nutrients. 2015 Feb 4;7(2):999-1020.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  52214-84-3